Alzheimer's Research & Therapy | Volume 3 Issue 3

Advanced search

Submit a manuscript Register Follow us on

Explore journal

Articles

cover

	Volume 3 Issue 3
	Comment
	Editorial Right sizing funding for Alzheimer's disease Todd E Golde, Bruce T Lamb, Douglas Galasko Alzheimer's Research & Therapy 2011, 3:17 (6 May 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary In their editorial, two of the journal’s Editors-in-Chief, and co-author Brian Lamb, call for additional funding to advance our understanding of this devastating disease and translate this into effective therapies.
	Review
	Review Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity Anne Eckert, Karen Schmitt, Jürgen Götz Alzheimer's Research & Therapy 2011, 3:15 (5 May 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Götz and colleagues review the critical role of mitochondria and the close interrelationship of this organelle with the two main pathological features in the pathogenic process underlying Alzheimer’s disease (AD).
	Review The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease Robert Vassar, Patty C Kandalepas Alzheimer's Research & Therapy 2011, 3:20 (31 May 2011) Abstract \| Full text \| PDF \| PubMed
	Review Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease Jake G Hoekstra, Kathleen S Montine, Jing Zhang, Thomas J Montine Alzheimer's Research & Therapy 2011, 3:21 (29 June 2011) Abstract \| Full text \| PDF \| PubMed
	Research
	Research Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell, Yijun Sun, Yikang Xu Alzheimer's Research & Therapy 2011, 3:22 (20 June 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Increasing the dose of donepezil to 23 mg/d may provide language benefits in patients with moderate to severe Alzheimer’s disease (AD), for whom preservation of language abilities is especially critical.
	Correspondence
	Letter Should persons with autosomal dominant AD be included in clinical trials? Joshua D Grill, John M Ringman Alzheimer's Research & Therapy 2011, 3:18 (23 May 2011) Abstract \| Full text \| PDF \| PubMed
	Letter Should persons with autosomal dominant AD be included in clinical trials? Authors' response Kinga Szigeti, Rachelle S Doody Alzheimer's Research & Therapy 2011, 3:19 (23 May 2011) Abstract \| Full text \| PDF \| PubMed